Marino Garcia Biography and Net Worth

President & Chief Executive Officer, Board Member of Dianthus Therapeutics

Mr. Garcia has served as our President and Chief Executive Officer since November 2021. Prior to joining Dianthus, Mr. Garcia served as Senior Vice President, Corporate and Business Development at Zealand Pharma A/S, a biotechnology company, from October 2018 to October 2021. Mr. Garcia previously served as Executive Vice President, Chief Strategy Officer at Synergy Pharmaceuticals from 2014 to 2018. Prior to Synergy, Mr. Garcia served as Head of Business Development for Aptalis Pharma when it was acquired by Forest Laboratories (now Allergan, an AbbVie Company) in 2014. Previously he served as Vice President, US Commercial Operations and Global New Product Development at Aspreva Pharmaceuticals, which was acquired by Vifor Pharma in 2007. Aspreva was developing CellCept (myocophenolate mofetil) for a range of autoimmune diseases, including Lupus Nephritis, Myasthenia Gravis, and Pemphigus Vulgaris. Mr. Garcia started his career in various commercial and strategic roles at large, multinational biopharmaceutical companies, including Merck & Co., Pfizer Inc. and Eli Lilly and Co. Mr. Garcia received his M.B.A. from the Ivey Business School at Western University in London, Ontario and his Bachelor of Commerce from Concordia University in Montreal, Quebec.

What is Marino Garcia's net worth?: The estimated net worth of Marino Garcia is at least $6.93 million as of August 7th, 2026. Mr. Garcia owns 65,292 shares of Dianthus Therapeutics stock worth more than $6,934,010 as of September 12th. This net worth evaluation does not reflect any other investments that Mr. Garcia may own. Learn More about Marino Garcia's net worth.
How do I contact Marino Garcia?: The corporate mailing address for Mr. Garcia and other Dianthus Therapeutics executives is 7 Times Square, 43rd Floor, New York, NY, 10036. Dianthus Therapeutics can also be reached via phone at (929) 999-4055 and via email at [email protected]. Learn More on Marino Garcia's contact information.
Has Marino Garcia been buying or selling shares of Dianthus Therapeutics?: During the last ninety days, Marino Garcia has sold $17,946,260.00 of Dianthus Therapeutics stock. Most recently, Marino Garcia sold 166,000 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a transaction totalling $17,946,260.00. Following the completion of the sale, the chief executive officer now directly owns 65,292 shares of the company's stock, valued at $7,058,718.12. Learn More on Marino Garcia's trading history.
Who are Dianthus Therapeutics' active insiders?: Dianthus Therapeutics' insider roster includes Edward Carr (Chief Accounting Officer), Marino Garcia (President & Chief Executive Officer, Board Member), Anne McGeorge (Director), Simrat Randhawa (Insider), Simon Read (Director), Ryan Savitz (CFO), and Adam Veness (SVP). Learn More on Dianthus Therapeutics' active insiders.
Are insiders buying or selling shares of Dianthus Therapeutics?: During the last twelve months, insiders at the sold shares 18 times. They sold a total of 849,767 shares worth more than $66,923,730.79. The most recent insider tranaction occured on September, 1st when EVP Simrat Randhawa sold 23,124 shares worth more than $2,460,624.84. Insiders at Dianthus Therapeutics own 3.0% of the company. Learn More about insider trades at Dianthus Therapeutics.
Information on this page was last updated on 9/1/2026.

Marino Garcia Insider Trading History at Dianthus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/7/2026	Sell	166,000	$108.11	$17,946,260.00	65,292
3/12/2026	Sell	122,918	$81.49	$10,016,587.82

Marino Garcia Buying and Selling Activity at Dianthus Therapeutics

Dianthus Therapeutics Company Overview

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Today's Range

Now: $106.20

$105.00

$109.79

50 Day Range

MA: $106.46

$93.34

$115.96

2 Week Range

Now: $106.20

$32.22

$117.88

Volume

732,760 shs

Average Volume

570,120 shs

Market Capitalization

$5.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24